Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KSR-001-02 (rebamipide)
- Development stage
- Unknown
- Lead developer
- Kukje Pharm
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
KSR-001-02 is a novel transparent rebamipide eye drop (1% concentration, containing 10 mg/mL rebamipide) developed by Kukje Pharma for the treatment of dry eye disease (DED). It is designed to improve tear film break-up time (TBUT), tear volume, and stabilize corneal staining scores in patients with dry eye syndrome. The eye drops are administered four times daily.
- Brand names
- RebaEye
- Other names
- 1% rebamipide clear solution
02
Targets
CCKAR (Cholecystokinin A receptor)Sts-1 HP (Suppressor of T cell signaling 1 phosphatase)MUC2 (Mucin-2)
Beyond the preview
Go deeper on KSR-001-02 (rebamipide).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KSR-001-02 (rebamipide).